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1ournal of Infection and Public Health (2014) 7, 245—246Table  1  Indications  for  pneumococcal  vaccination.
Risk  factor/indication  No.  (percentage)
Diabetes  mellitus 40  (53.3%)
Chronic  heart  failure 19  (25.3%
Chronic  renal  failure  12  (16%)
Chronic  lung  disease  8  (10.7%)
Immunocompromised  8  (10.7%)
Smoker  3  (4%)
Alcohol  1  (1.3%)
Asplenism  1  (1.3%)
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NETTER TO THE EDITOR
oward  reducing  the  burden  of  pneumococcal
isease in  the  Gulf  States
ear  Editor,
In an  article  titled  ‘‘Pneumococcal  disease  in
he Arabian  Gulf:  Recognizing  the  challenge  and
oving  toward  a  solution’’  [1], Feldman  et  al.
ighlighted  the  seriousness  of  the  threat  of  inva-
ive pneumococcal  disease  for  the  populations  of
he gulf  region.  As  the  authors  determined,  the
rimary  driving  forces  for  the  increased  suscepti-
ility of  these  nations  are  the  increasing  numbers
f vulnerable  older  individuals  and  the  escalating
revalence of  chronic  diseases,  such  as  diabetes
ellitus. On  behalf  of  the  Gulf  Advocacy  Group,
he authors  called  on  healthcare  providers  and
olicy  makers  in  the  Gulf  States  ‘‘to  take  steps
oward addressing  unmet  needs  to  ease  the  burden
f pneumococcal  disease  in  adults’’.  The  authors
uggested  several  interventions  to  achieve  better
mplementation  of  the  CDC  guidelines  [2]  on  the
se of  polyvalent  pneumococcal  vaccination  includ-
ng unifying  vaccination  policies  across  the  region,
mproving  disease  epidemiological  surveillance  and
ncreasing awareness  among  healthcare  providers
nd the  public.
During  a  recent  ‘‘one-day’’  surveillance  exer-
ise, the  Knowledge  Translation  Committee  of  the
epartment  of  Medicine  at  King  Abdul-Aziz  Medical
ity (a  tertiary  care  center  in  Riyadh,  Kingdom  of
audi Arabia)  attempted  to  gauge  patients’  knowl-
dge of  the  pneumococcal  vaccine  and  determine
hether any  patient  has  ever  been  offered  or
eceived the  vaccine.  Participants  were  all  acutely
dmitted  internal  medicine  patients  who  were
vailable  on  the  day  of  the  exercise  and  who  agreed
o participate.  Seventy-ﬁve  (75)  patients  from  four
edical wards  were  surveyed.  The  average  age
as 69.8  years  (range  17—99)  and  44  (58.7%)  were
ale.
As per  the  CDC  guidelines,  67  individuals
89.3%) had  an  indication  for  receiving  the
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accine  (Table  1).  Age  was  the  only  indication
n 18  participants  (26.9%).  Twenty-ﬁve  individuals
37.3%)  had  one  risk  factor,  18  (26.9%)  had  two  risk
actors,  5  (7.5%)  had  three  risk  factors  and  one
1.5%) had  four  risk  factors.  None  of  the  partici-
ants has  ever  had  the  vaccine  or  heard  of  it.
Despite the  limitations  of  our  exercise  (e.g.,  ter-
iary care  center,  highly  selected  population,  recall
oncerns,  educational  levels),  our  ﬁndings  high-
ight the  same  issues  that  were  raised  by  Feldman
t al.  in  their  article,  especially  regarding  the  vac-
ination of  adults,  and  emphasizes  the  need  for
oncerted  action  to  raise  awareness  (and  uptake)
f vaccination  against  pneumococcal  disease  among
ealthcare  professionals  and  the  public.
Taking  a  step  toward  a  solution,  the  knowledge
ransmission committee  in  King  Abdul-Aziz  Med-
cal City  has  set  plans  for  education  about  the
neumococcal vaccine  and  intervention  to  improve
accination  compliance  in  hospitals.
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